CORPORATE SUPPORT. AstraZeneca

Similar documents
MAXIMIZE RADIAL SOLUTIONS TO PERIPHERAL CHALLENGES

ADVANTAGES AND DISADVANTAGES OF CATHETER MATERIALS TABLE 9 ADVANTAGES AND DISADVANTAGES OF CATHETER MATERIALS... 43

Guidewires Market Analysis, Size, Share, Growth, Industry Trends and Forecast to Hexa Research

France Interventional Cardiology Market Outlook to 2020

Percutaneous Transluminal Angioplasty Balloons - Medical Devices Pipeline Assessment, 2016

Challenging of contrast agent-free endovascular treatment using 3D imaging

PressureWire Aeris with Agile Tip Technology. Wireless FFR Functionality and Handles like a Workhorse PCI Guidewire 1

Hybrid Procedures for Peripheral Obstructive Disease - Step by Step -

FFR/IFR Should Not be the Gold Standard for Intervention Decisions

INTRODUCING. Cordis POWERFLEX Pro PTA Dilatation Catheter

Primary Results of the Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement Study

For Personal Use. Copyright HMP 2013

Device Evolution. Atherectomy: Where Do We Stand After 12 Years Since FDA Clearance. Where Do We Stand? 4/18/2015

Rationale and algorithm for below-the-knee acute gain optimization

Step by step Hybrid procedures in peripheral obstructive disease. Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery

Latest Insights from the LEVANT II study and sub-group analysis

COMPANY INTRODUCTION: PROFILE & PRODUCTS

History of the Powerlink System Design and Clinical Results. Edward B. Diethrich Arizona Heart Hospital Phoenix, AZ

IVUS Guided Case Review Case Performed by Frank R. Arko III, MD Charlotte, NC

Copyright HMP Communications

U.S. Markets for Interventional Cardiology Products

INNOVATIVE TWO-IN- ONE FUNCTIONALITY. ARROW GPSCATH FEATURING VISIOVALVE Navigate with confidence

Solving the Dilemma of Ostial Stenting: A Case Series Illustrating the Flash Ostial System

Recent Advances in Peripheral Salvage

ISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany

Cordis ExoSeal. Maximise Clinical Safety*. The novel approach to secure and easy closure. Vascular Closure Device CORDIS EXOSEAL VCD

Christian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide

Lessons learnt from DES in the SFA is there any ideal concept so far?

Stents for The Common Femoral Artery: The Good, The Bad and The Ugly

Appropriate Device Selection for Endovascular Procedures

National Intervention Council

Accurate Vessel Sizing Drives Clinical Results. IVUS In the Periphery

Maximise Clinical Safety*. Cordis ExoSeal. The novel approach to secure and easy closure. Vascular Closure Device CORDIS EXOSEAL VCD

Update on the Levant 2 Clinical Trial Programme. Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany

Cardiologic history. Anamnesis. Female BD Risk factors HTN, DM, Dyslipidaemia. Cardiologic Long history. Last admission Heart failure

Global Peripheral Artery Disease Market: Trends & Opportunities ( ) February 2016

Boston Scientific is advancing...

PATIENT SPECIFIC STRATEGIES IN CRITICAL LIMB ISCHEMIA. Dr. Manar Trab Consultant Vascular Surgeon European Vascular Clinic DMCC Dubai, UAE

Navigate Complex Interventions at Every Turn

Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT)

Cleveland Clinic Innovation Center

Straub Endovascular System &

New Modalities and Advanced Techniques: The Role of Crossing Devices and Atherectomy

Long-term results with interwoven nitinol stents vs. BMS vs. DCB

The Wright Grou. the history of

REFERENCE CODE GDME1058CFR PUBLICATION DATE SEPTEMBER 2013 DRUG-ELUTING BALLOONS APAC ANALYSIS AND MARKET FORECASTS

Atherectomy: Jetstream and Directional. George S. Chrysant, M.D.

Tools and options for recanalisation of long-femoro-popliteal segments

SAMPLE. South and Central America Drug Delivery Devices Market Outlook to Metered Dose Inhaler Devices, Infusion Systems, Central

TRANSRADIAL PERIPHERAL VASCULAR INTERVENTIONS

Robert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015

CLI Treatment Using Long and Scoring Balloons

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

5F Devices with 0.035

Making BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD

Leg arteries : MANAGEMENT and STRATEGY

One Year after In.Pact Deep: Lessons learned from a failed trial. Prof. Dr. Thomas Zeller

N a s d a q : I N S Y

Interactive Tool Box for Below The Knee selected by Max Amor & Joseph Azzi.

Welcome to the 8 th European Bifurcation Club October Barcelona

Shockwave Intravascular Lithotripsy System treatment of calcified lesions: Intravascular OCT analysis

Endovascular Repair of Combined Occluded Femoral and Popliteal Arteries

Chronic Total Occlusion (CTO) Technologies

Complex Coronary Interventions: Bifurcations. John M. Lasala MD PhD Professor of Medicine Washington University St Louis, Missouri

Hybrid surgical treatment of bilateral aorto-femoral occlusion: a clinical case

Maximizing Outcomes in a complex population with Drug-coated balloon

Update on the OPTIMIZE BTK Trial. Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria

Turbo-Power. Laser atherectomy catheter. The standard. for ISR

Angiographic dissection pattern and patency outcomes of post balloon angioplasty for SFA lesions -a retrospective multi center analysis-

The essentials for BTK procedures: wires, balloons, what else

Guidewire Selection. Making the Most Out of My Guidewire: LINC 2016: Leipzig Interventional Course Leipzig, Germany January 26-29, 2016

Ping-Pong Guide Catheter Technique for Retrograde Intervention of a Chronic Total Occlusion Through an Ipsilateral Collateral

Present & future of below the knee stenting

Coronary Plaque Sealing: The DEFER Study and more...

New Devices Pedro Pinto Cardoso

Quality Medical Donations

The Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience

The Case of the successful PCI for the ostium CTO lesion of the RCA by the retrograde approach

PERFORMANCE YOU CAN TRUST. EverFlex Self-expanding Peripheral Stent with Entrust Delivery System

Joint Working Group to produce guidance on delivering an Endovascular Aneurysm Repair (EVAR) Service.

Optimal Techniques for Obtaining Large Caliber Arterial Access

Max Medical Devices.

Can t See the Forest for the Trees: Transcollateral Crossing of Chronic Total Occlusions

Evolution In Interventional Cardiology. Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands

Comparison of Angiographic Dissection Patterns Caused by Long vs Short Balloons During Balloon Angioplasty for Chronic Femoropopliteal Occlusions

Coronary angiography and PCI

Introduction What Causes Peripheral Vascular Disease? How Do Doctors Treat Peripheral Vascular Disease?... 9

Do we really need a stent in long SFA lesions? No: DEB is the answer

SUNY UPSTATE MEDICAL UNIVERSITY. Clinical Update March #1 Consumer Choice

Working at Boston Scientific. Ronan Emmett Human Resources

Lutonix AV Clinical Trial

Calcified lesions optimal treatment

NC EMERGE TM PTCA Dilatation Catheter

Crossing the Long SFA CTO

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

Clinically proven. ordering info. Vascular Intervention // Peripheral Self-Expanding Stent System/0.018 /OTW. Pulsar-18

TOBA II 12-Month Results Tack Optimized Balloon Angioplasty

Critical limb ischemia due to an occlusion of an aorto-biiliac prothesis step by step case presentation and decision making

Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort

Miami Valves, Miami Florida. Cardiovascular Associates of South Florida

Transcription:

CORPORATE SUPPORT The 28 th Annual Cardiovascular Interventions is supported, in part, by educational grants and exhibits from industry, in accordance with the ACCME Accreditation Standards for Commercial Support. We gratefully acknowledge and thank the following contributors who have given generously to support this program via educational grants and/or an exhibit. At Abbott, we re committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world in nutrition, diagnostics, medical devices and branded generic pharmaceuticals that create more possibilities for more people at all stages of life. Today, 74,000 of us are working to help people live not just longer, but better, in the more more than 150 c0untries we serve. Connect with us at www.abbott.com, on Facebook at www.facebook.com/abbott and on Twitter @AbbottNews and @AbbottGlobal. Abiomed (NASDAQ: ABMD) is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. CEO, Chairman, and President Michael R. Minogue has focused the company s efforts on developing ground-breaking technologies designed to improve the patient outcomes focused on native heart recovery. Founded in 1981 for the purpose of developing the world s first artificial heart, Abiomed has remained dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians. ACIST, a Bracco Group company, offers innovative technologies that simplify cardiovascular procedures and empower clinicians. The portfolio includes: CVi variable rate contrast injector, RXi the first and only Rapid FFR MicroCatheter system and HDi High Definition IVUS system. Asahi Intecc is a medical device company focused on delivering clinically unique devices used in vascular procedures by interventional cardiologists, interventional radiologists, vascular surgeons and neurovascular surgeons. Asahi will leverage its four core competencies to develop device-based solutions targeting specific niches where Asahi can achieve a market leading position. AstraZeneca

Great ideas and great technologies can transform patient care. That s why at Bard Peripheral Vascular we offer a wide range of transformative medical devices for the peripheral vasculature including: The LUTONIX 035 Drug Coated Balloon PTA Catheter is optimized to effectively treatt lesions in the SFA, Full Popliteal, In-Stent Restenosis and Long Lesions with the ideal formulation and dosage designed for patient safety. Pleasee consult package inserts for more detailed safety information and instructions for use. Cardiovascular Systems, Inc. (CSI) is leading the way in the effort to successfully treat arterial calcium, a common complication for millions of patients suffering from peripheral and coronary artery diseases. CSI s mission is to develop and commercialize innovative solutions that help physicians save limbs and lives when facing this difficult-to-treat disease state. CSI is committed to clinical rigor, constant innovationn and a defining drive to set the industry standard to deliver safe and effective medical devices that improve lives. Chiesi USA, Inc., headquartered in Cary, NC, is a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets. Visit www.chiesiusa..com for more information. Cook Medical Edwards Lifesciences

GE Healthcare Gilead Medicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market. The Company s current focus is in the area of acute cardiovascular care, a market served by its commercial product, AGGRASTAT (tirofiban HCl). National Board of Physicians and Surgeons (NBPAS) Novartis Pharmaceuticals The latest in fractional flow reserve (FFR) guidewire technology! OptoWire, the first FFR pressure guidewire with workhorse wire performance, combines next-generation fiber-optic technology with a nitinol core and worry-free reconnector. OptoWire maneuvers across complex anatomy, measures FFR, and delivers stents using a single wire, for a One-Wire PCI experience! Visit Opsens Medical in the exhibit hall at Scripps Cardiovascular Interventions 2017!

Ostial Corporation is dedicated to providing a reliable solution to the challenges of aorto-ostial stenting. FLASHTM Ostial System is designed to stabilize, post-dilate and conform the stent to the ostium during ostial post-stent dilation and angioplasty. The proprietary dual balloon design enables the physician to achieve maximal stent wall apposition after post-dilation and result in treating Ostial lesions. The FLASHTM is available for both coronary and peripheral indications. Philips Volcano, a Philips business, is a global leader in physiology and intravascular imaging for coronary and peripheral applications. The business also offers a suite of peripheral therapeutic devices. This is part of Philips industry leading solutions to decide, guide and confirm the right therapy for each patient in real-time during image-guided therapies. Founded in cardiovascula care and expanding into other specialties, Philips is focused on improving patient and economic outcomes. Sanofi Aventis Siemens Healthcare Spectra anetics, A Philips Company St. Jude Medical

Teleflex is a global provider of medical technologies designed to improve the health and quality of people s lives. We apply purpose driven innovation a relentless pursuit of identifying unmet clinical needs to benefit patients and healthcare providers. With Teleflex and the recent acquisition of Vascular Solutions, our new Interventional division offers a growing portfolio of innovative, specialty-focused solutions to support interventionalists around the world. Terumo Interventional Systems (TIS), a division of Terumo Medical Corporation, is a market leader in minimally invasive entry site management and lesion access technologies. TIS offers a complete, solution-based product portfolio used in advanced coronary, peripheral endovascular and urological treatments with strategic initiatives in Transradial Access, Complex Coronary Intervention and Critical Limb Ischemia. TIS combines innovative research and development with a deep market understanding to create a pipeline of industry leading devices that deliver clinical value, economic benefit, and enhanced patient outcomes. TriReme Medical, Inc.